Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Non-Current Assets: 2018-2024

Historic Non-Current Assets for Whitehawk Therapeutics (WHWK) over the last 7 years, with Dec 2024 value amounting to $9.0 million.

  • Whitehawk Therapeutics' Non-Current Assets fell 76.37% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 76.37%. This contributed to the annual value of $9.0 million for FY2024, which is 15.25% up from last year.
  • According to the latest figures from FY2024, Whitehawk Therapeutics' Non-Current Assets is $9.0 million, which was up 15.25% from $7.8 million recorded in FY2023.
  • In the past 5 years, Whitehawk Therapeutics' Non-Current Assets ranged from a high of $9.0 million in FY2024 and a low of $140,000 during FY2020.
  • Its 3-year average for Non-Current Assets is $7.0 million, with a median of $7.8 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 61.78% in 2020, then soared by 4,641.43% in 2021.
  • Yearly analysis of 5 years shows Whitehawk Therapeutics' Non-Current Assets stood at $140,000 in 2020, then skyrocketed by 4,641.43% to $6.6 million in 2021, then crashed by 36.61% to $4.2 million in 2022, then surged by 86.24% to $7.8 million in 2023, then grew by 15.25% to $9.0 million in 2024.